Last reviewed · How we verify
Non biologically active gel
Non biologically active gel does not have a known mechanism of action.
At a glance
| Generic name | Non biologically active gel |
|---|---|
| Also known as | Hydrogel |
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a non biologically active gel, it does not interact with biological systems in a way that would produce a therapeutic effect. Its purpose is likely to serve as a placebo or control in clinical trials.
Approved indications
Common side effects
Key clinical trials
- Beta Adrenergic Antagonist for the Healing of Chronic DFU (PHASE3)
- Safety and Efficacy Trial of TV5M01 for Radiation-Induced Mucositis in Head and Neck Cancer Patients. (PHASE1, PHASE2)
- The ENRGISE (ENabling Reduction of Low-Grade Inflammation in SEniors) Pilot Study (PHASE2)
- Combination of Diclofenac Potassium and Propolis in the Therapy of Oral Aphthosis (EARLY_PHASE1)
- Use of Ozone Gel as an Antimicrobial in Treatment of Periodontitis (PHASE1)
- A Study to Evaluate Safety and Immunogenicity of FluvalAB-like Influenza Vaccine in Non-Elderly Adult and Elderly Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Non biologically active gel CI brief — competitive landscape report
- Non biologically active gel updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI